Maravai LifeSciences (MRVI) Projected to Announce Quarterly Earnings on Wednesday

Maravai LifeSciences (NASDAQ:MRVI) is expected to post its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect Maravai LifeSciences to announce earnings of ($0.0563) per share and revenue of $43.56 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 5:00 PM ET.

Maravai LifeSciences (NASDAQ:MRVI) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.02. The firm had revenue of $51.44 million for the quarter, compared to the consensus estimate of $48.67 million. On average, analysts expect Maravai LifeSciences to post ($0.18) EPS for the current fiscal year and ($0.13) EPS for the next fiscal year.

Maravai LifeSciences Trading Up 0.9%

Shares of NASDAQ:MRVI traded up $0.07 during trading on Wednesday, reaching $8.34. The stock had a trading volume of 317,302 shares, compared to its average volume of 2,473,369. The firm’s fifty day moving average is $7.43 and its 200 day moving average is $5.17. Maravai LifeSciences has a 52 week low of $2.55 and a 52 week high of $9.42.

Analyst Ratings Changes

MRVI has been the subject of a number of recent analyst reports. Wells Fargo & Company upped their price objective on shares of Maravai LifeSciences from $5.50 to $6.50 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maravai LifeSciences in a research note on Wednesday, August 26th. TD Cowen assumed coverage on Maravai LifeSciences in a research report on Monday, October 5th. They set a “buy” rating and a $9.00 price target for the company. Wall Street Zen downgraded shares of Maravai LifeSciences from a “buy” rating to a “hold” rating in a research note on Saturday, August 29th. Finally, UBS Group upped their price objective on shares of Maravai LifeSciences from $2.50 to $8.00 and gave the stock a “neutral” rating in a report on Wednesday, September 9th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $7.38.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc is a life sciences company that provides products and services used in the development, manufacture and quality testing of biopharmaceuticals, vaccines and diagnostic products. The company serves pharmaceutical, biotechnology, academic and other research organizations involved in nucleic acid and biologics development.

Through its TriLink BioTechnologies business, Maravai supplies specialized nucleic acid products and services, including modified nucleotides, messenger RNA-related materials, enzymes and other components used in research and biomanufacturing.